ArticleJournal of hepatocellular carcinoma2025
A CT-Based Deep Learning Radiomics Scoring System for Predicting the Prognosis to Repeat TACE in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence in Hepatocellular Carcinoma: Current Applications, Clinical Performance, and Barriers to Implementation.Journal of clinical medicine · 2026Review
- Artificial Intelligence in the Diagnosis and Prognostic Stratification of Hepatocellular Carcinoma: Current Evidence, Clinical Applications, and Future Perspectives.Biomedicines · 2026Review
- Deep learning techniques for using computed tomography imaging for hepatocellular carcinoma diagnosis, treatment and prognosis.World journal of gastroenterology · 2026Review
- Artificial intelligence in transarterial chemoembolization for hepatocellular carcinoma: from treatment response prediction to refractoriness assessment.Frontiers in oncology · 2026Review
- MRI-Based Deep Learning and Radiomics Nomogram for Predicting Hepatocellular Carcinoma Recurrence Within Six Months After Thermal Ablation.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to construct a novel retreatment scoring system to screen patients with hepatocellular carcinoma (HCC) who could benefit further after transarterial chemoembolization (TACE). Patients and Methods: 310 patients with HCC were retrospectively recruited from three hospitals. The training and validation cohort were randomly selected from Center 1, and two external testing cohorts comprised from Center 2 and Center 3, respectively. Deep learning score and handcrafted radiomics signatures were constructed from the pretreatment arterial-phase and venous-phase CT images. The optimal features were screened using SelectKBest and LASSO regression. The AUC of the optimal combined model, consisting of HBsAg, five radiomics features, and DLscore, was 0.97, 0.89, 0.76, and 0.84 in the four cohorts, respectively. The optimal model was well calibrated. The prediction performance was assessed with respect to receiver operating characteristics, calibration, and decision curve analysis. Kaplan-Meier survival curves based on the scoring system were used to estimate the overall survival (OS). Results: The optimal combined model consisted of HBsAg, 5 radiomics signatures, and DLscore, which AUC in four cohorts was 0.97, 0.89, 0.76, and 0.84, respectively, with good calibration. Decision curve analysis confirmed that the combined model was clinically useful. After Cox regression analysis of these characteristics, the scoring system (HBsAg-Radscore-DLscore, HRD) was significantly associated with OS in patients with HCC, and was superior to the traditional ART score and ABCR score between high and low-risk patients. Conclusion: Deep learning and radiomics had good performance in predicting the OS of patients with HCC treated with repeated TACE. The HRD score is a potentially valuable and intelligent prognostic scoring system better than the traditional score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.